Cytokinetics’ (CYTK) investigational product omecamtiv mecarbil, the firm’s potential treatment for heart failure with reduced ejection fraction, is advancing in a late phase clinical trial. Cytokinetics is conducting METEORIC-HF clinical trial, in collaboration with Amgen (AMGN), with funding and strategic support from Servier. The trial aims at evaluating the effect of omecamtiv mecarbil compared to placebo on exercise capacity as determined by cardiopulmonary exercise testing (CPET) in patients …

UCART19 UCART19 is one of the Cellectis’ (CLLS) lead allogeneic anti-CD19 CAR T-cell products. The word allogeneic is important as it makes the difference between Cellectis’ CAR T products and the two approved chimeric antigen receptor (CAR T) products and some of the investigational CAR T immuno-oncology products. Except for Cellectis’ and a few other  biotechs including  Celyad’s (CYAD)  products all other CAR T treatments are non-allogeneic (autologous) treatments. Being allogeneic, Cellectis’ products …

– Exclusively licenses global rights to its (TGFb) antibody program to Novartis  – Could the lucrative agreement spare Xoma the pain of raising money for developing its programs, or filing bankruptcy?  – Reasons to believe that Xoma’s TGFb therapeutic antibodies might become another cancer immunotherapy used alone or in combination with immune checkpoint protein inhibitors such as PD-1 inhibitors, which are considered game changers in …

Xoma (XOMA) announced good news from Phase 3 EYEGUARD-B trial of its monoclonal antibody drug gevokizumab for Behcet’s uveitis. The study, which is sponsored by Xoma’s development partner Servier, reached its target exacerbation event as specified in the study design. The objective of the first part of this study is to demonstrate the superiority of gevokizumab, inreducing the risk of Behcet’s disease uveitis exacerbation and …